Retatrutide vs tirzepatide — two of the most-discussed GLP-1 class compounds for weight management. They share a weekly injection schedule but target different hormonal pathways. Here's what the research shows and what questions to bring to your TelosRX evaluation, subject to medical approval by a licensed provider.
The GLP-1 space moves fast. Tirzepatide raised the bar when it launched with 20%-plus weight loss data. Now retatrutide is generating serious Phase 2 and Phase 3 trial results. If you're trying to understand the difference before speaking with a provider, this breakdown covers the science in plain language — mechanism, clinical data, side effects, and what to expect.
Retatrutide vs Tirzepatide: Head-to-Head Comparison
Here's how these two compounds stack up on the factors that matter most clinically.
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1 + GIP (dual agonist) | GLP-1 + GIP + Glucagon (triple agonist) |
| FDA approval status | Approved for T2D (2022) and weight management (2023) | Not FDA-approved; Phase 3 trials ongoing |
| Peak weight loss (highest dose) | ~22.5% at 72 weeks (SURMOUNT-1) | ~24.2% at 48 weeks (Phase 2); Phase 3 data pending |
| Liver fat reduction | Significant improvement in trials | Up to 85% resolution of hepatic steatosis (subset data) |
| Heart rate effect | Minimal reported change | Dose-dependent, transient increase (peaks ~week 24) |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Compounded access | Subject to provider-issued prescription | Subject to provider-issued prescription; regulatory status evolving |
How Each Drug Works: Dual vs Triple Agonist
The practical difference between these compounds starts with receptor count — but more receptors doesn't automatically mean better. It changes how the drug interacts with your metabolism.
How Tirzepatide Works
Tirzepatide activates two hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 slows gastric emptying, reduces appetite signals in the brain, and improves insulin response after meals. GIP works alongside it, enhancing fat metabolism and amplifying the appetite-suppressing effect.
Together, they produced the first published trial data showing 20%-plus weight reduction in a non-surgical setting. The SURMOUNT-1 Phase 3 trial reported a mean 22.5% weight reduction at the 15 mg dose over 72 weeks, with over 60% of participants in the highest-dose group achieving 20% or more weight loss. These numbers had not been seen before in a pharmaceutical weight loss trial.
Tirzepatide also demonstrated a 94% reduction in progression to type 2 diabetes among participants with prediabetes — a finding that shifted how clinicians think about GLP-1 therapy beyond just weight loss.
How Retatrutide Works
Retatrutide adds a third receptor target: the glucagon receptor. Glucagon was traditionally understood as the counterpart to insulin — it raises blood sugar. But glucagon receptor activation, when combined with GLP-1 and GIP signaling, produces different effects than glucagon does alone.
The result appears to be increased energy expenditure — more calories burned at rest — on top of appetite suppression. Retatrutide also shows particular activity in the liver, which is where its fatty liver data comes from.
In its Phase 2 NEJM trial, retatrutide produced a mean 24.2% weight reduction at 48 weeks at the 12 mg dose — and importantly, participants had not yet reached a weight plateau when the study ended, suggesting the ceiling may be higher. Retatrutide is not FDA-approved and remains under Phase 3 investigation.
Clinical Efficacy: What the Trial Data Shows
Comparing trial results directly is tricky. Tirzepatide's SURMOUNT-1 data ran for 72 weeks. Retatrutide's Phase 2 data ran for 48 weeks — different populations, different durations, different doses. You can't simply say one is X% better than the other from this data alone.
What you can say:
- Retatrutide's 24.2% mean weight loss at 48 weeks is the highest average percentage recorded in any single pharmaceutical weight loss trial to date.
- Tirzepatide has 72-week and three-year safety data; retatrutide's long-term safety record is still being built.
- Both exceed the weight loss seen with semaglutide alone at comparable doses.
- A head-to-head Phase 3 comparison trial, TRIUMPH-5, is actively comparing the two directly, with results expected in late 2026 or 2027.
The question your provider will ask isn't which trial number is bigger. It's which mechanism fits your individual metabolic profile and health history.
Muscle Preservation: A Key Consideration on Both Compounds
Every meaningful weight loss intervention comes with some lean mass reduction. That's true of caloric restriction, bariatric surgery, and GLP-1 therapy. The question is whether the proportion of fat loss vs. lean mass loss is favorable for your goals.
DXA scan data from SURMOUNT-1 showed approximately 75% fat mass loss and 25% lean mass loss on tirzepatide — a ratio that's generally considered favorable for significant weight loss, though not ideal for highly active individuals or people at lower body weights. Comparable published body composition data for retatrutide from Phase 3 trials is not yet available.
The strategies for minimizing muscle loss are the same regardless of which compound a provider approves: resistance training at least two to three times per week and adequate protein intake (research generally supports 1.2–1.6 grams per kilogram of body weight for people on GLP-1 therapy).
For a deeper dive into this topic, see our guide on preserving lean mass on GLP-1 therapy.
Ready to discuss your options? Start your asynchronous evaluation at TelosRX — subject to medical approval by a licensed provider — and your provider will factor in your muscle mass and activity level as part of the review.
Side Effects: Where Tirzepatide and Retatrutide Overlap and Differ
Both compounds share the GLP-1 class side effect profile. The most common reactions:
- Nausea — most common, particularly during dose escalation
- Diarrhea or constipation — often one or the other, depending on the individual
- Acid reflux or belching — from slowed gastric emptying
- Decreased appetite — an intended effect, but can become excessive at high doses
- Fatigue — often early-stage during titration
These effects are typically dose-dependent and improve as the body adjusts. Slow titration — the standard protocol — is the most effective way to reduce them. Our guide on managing GLP-1 side effects covers practical strategies in detail.
Where retatrutide differs: Phase 2 data flagged a dose-dependent, transient increase in heart rate tied specifically to glucagon receptor activation. In that trial, the heart rate increase peaked around week 24 and declined afterward. This is not seen with tirzepatide to the same degree. Anyone with a history of cardiac arrhythmia or other heart conditions should raise this with a provider before any evaluation.
Liver Fat and Metabolic Health: Where Retatrutide Stands Out
The liver fat data for retatrutide is arguably its most compelling differentiator. In a subset analysis from the Phase 2 trial, retatrutide resolved hepatic steatosis (fatty liver) in over 85% of participants receiving higher doses. Tirzepatide also demonstrates significant liver fat reduction, but the glucagon receptor component in retatrutide may give it a particular advantage for people with meaningful liver fat accumulation.
This matters for a specific population: people with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/NASH) face serious downstream cardiovascular and metabolic risks. If liver fat is a significant part of your clinical picture, this distinction could be meaningful — though your provider needs to assess it in the context of your full health profile.
People interested in broader metabolic interventions may also want to read about cagrilintide, which targets a different pathway (amylin receptor) and has shown synergistic effects when combined with semaglutide.
Compounded Retatrutide: Access and Regulatory Status
Tirzepatide became available as a compounded compound during periods when the branded version was in shortage, and a clear regulatory pathway existed. Retatrutide's situation is different — and more complicated.
Retatrutide is not FDA-approved. Any compounded version of retatrutide is not FDA-approved and is being prepared outside of a completed clinical trial context. Compounded retatrutide has appeared through various online channels, but quality control, dosing accuracy, and sterility standards vary widely without oversight.
At TelosRX, any compounded compound — whether tirzepatide or any emerging GLP-1 class agent — requires evaluation and a provider-issued prescription before access. Our asynchronous model means you don't need to schedule a synchronous call: submit your intake, and a licensed provider reviews it on their end. Approval is not guaranteed and depends on your individual clinical picture.
For more context on retatrutide's clinical development, see our overview: Retatrutide Weight Loss: Triple-Agonist GLP-1 Explained.
Which Option Should You Consider?
No compound is right for everyone. Here's a framework based on current evidence — and the questions worth bringing to your provider:
- If you prioritize an established safety record: Tirzepatide has three-plus years of data, defined titration protocols, and real-world experience. It's the stronger first-choice candidate for most people starting GLP-1 therapy.
- If you have significant liver fat involvement: Retatrutide's glucagon receptor activity shows a meaningful signal for hepatic fat reduction. Worth discussing if fatty liver is part of your clinical picture.
- If you've plateaued on a dual agonist: The third pathway retatrutide adds may offer additional metabolic leverage, though this is still speculative until Phase 3 data arrives.
- If cardiac history is a concern: The transient heart rate increase seen with retatrutide makes tirzepatide the safer initial option.
Your provider will factor your metabolic labs, cardiovascular history, liver function, activity level, and goals before recommending any compound. That's the right order of operations.
Frequently Asked Questions
Is retatrutide available now?
Retatrutide is not FDA-approved and remains in Phase 3 clinical trials. Compounded retatrutide exists online but is not regulated as a prescription drug and carries quality and safety risks. Any access to a compounded GLP-1 compound through TelosRX is subject to medical approval by a licensed provider following an asynchronous evaluation.
Is retatrutide more effective than tirzepatide?
Phase 2 data shows higher mean weight loss with retatrutide at 48 weeks compared to tirzepatide at 72 weeks, but a direct comparison isn't valid until the TRIUMPH-5 head-to-head trial reports. Effectiveness also depends on individual metabolic factors — more receptor targets isn't always better for a given patient.
Can retatrutide cause muscle loss?
Any meaningful weight loss, including from GLP-1 compounds, involves some lean mass reduction. Retatrutide Phase 3 body composition data isn't published yet. Resistance training and adequate protein intake are the primary strategies for lean mass preservation on any GLP-1 protocol, subject to provider guidance.
What is the main mechanistic difference?
Tirzepatide activates GLP-1 and GIP receptors (dual agonist). Retatrutide activates GLP-1, GIP, and glucagon receptors (triple agonist). The glucagon component increases energy expenditure and has shown significant effects on liver fat reduction — that's the core practical difference between the two.
Does retatrutide increase heart rate?
Phase 2 data documented dose-dependent, transient heart rate increases with retatrutide, peaking around week 24 and declining afterward. This is a specific concern for people with cardiac history and should be explicitly discussed with a provider before requesting any evaluation involving retatrutide.
Is compounded tirzepatide or retatrutide FDA-approved?
No. Compounded versions of tirzepatide and retatrutide are not FDA-approved. Compounded medications are prepared under federal compounding regulations and require a provider-issued prescription. Only branded FDA-approved tirzepatide versions carry FDA approval for labeled indications.
How does TelosRX handle GLP-1 evaluations?
TelosRX operates as an online-first, asynchronous telehealth service. You submit your health intake and a licensed provider reviews it on their schedule — no synchronous video call is required. If medically appropriate, a provider-issued prescription is issued. Approval is not guaranteed.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.